RIGL Rigel Pharmaceuticals, Inc.

3.03
0  -1%
Previous Close 3.05
Open 3.05
Price To book 5.51
Market Cap 370.52M
Shares 122,285,000
Volume 729,870
Short Ratio 2.82
Av. Daily Volume 1,305,760

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 preliminary data released January 5, 2017. Enrollment of second cohort to be completed in 2017 with data due in 2018.
Fostamatinib
IgA nephropathy
Phase 2 trial did not meet endpoints
R348
Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD)
Phase 3 data from the first trial released August 30 2016. Primary endpoint met. Data from second trial did not meet the primary endpoint. NDA submission announced April 17, 2017.
Fostamatinib
Immune Thrombocytopenic Purpura (ITP)
Phase 2 data from first of two stages due in 2017.
Fostamatinib
Autoimmune hemolytic anemia (AIHA)

Latest News

  1. Rigel Pharmaceuticals Files NDA for Thrombocytopenia Drug
  2. Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
  3. 5 Top Breakout Stocks to Boost Your Portfolio
  4. Increased Earnings Estimates Seen for Rigel (RIGL): Can It Move Higher?
  5. After Years of Stagnation, Are Shares of Rigel Pharmaceuticals About to Take off Into the Stratosphere?
  6. Will Rigel Pharmaceuticals (RIGL) Continue to Surge Higher?
  7. 3 Beaten-Up Biotech Stocks: Are They Bargains?
  8. 3 Stocks That Are Ridiculously Cheap Right Now
  9. 5 Cheap Breakout Stocks for Superb Returns
  10. Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017
  11. Edited Transcript of RIGL earnings conference call or presentation 7-Mar-17 10:00pm GMT
  12. Rigel reports 4Q loss
  13. Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update
  14. Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2016 Financial Results
  15. 3 Cheap Healthcare Stocks You Can Buy Right Now
  16. Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
  17. Rigel Announces Pricing Of Public Offering Of Common Stock
  18. Rigel Announces Proposed Public Offering Of Common Stock
  19. Why the Rigel Pharmaceuticals Update Could Signal Further Growth
  20. Fostamatinib Study Results Continue to Trend Positive